MRNA vs. JPM
MRNA (Moderna, Inc.) and JPM (JPMorgan Chase & Co.) are both stocks. MRNA operates in Biotechnology (Healthcare), while JPM operates in Banks - Diversified (Financial Services). Over the past 5 years, MRNA returned -24.19%/yr vs 16.21%/yr for JPM. At a 0.16 correlation, their price movements are largely independent.
Performance
MRNA vs. JPM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MRNA achieves a 74.94% return, which is significantly higher than JPM's -2.59% return.
MRNA
- 1D
- 5.16%
- 1M
- 10.45%
- YTD
- 74.94%
- 6M
- 102.39%
- 1Y
- 89.18%
- 3Y*
- -26.31%
- 5Y*
- -24.19%
- 10Y*
- —
JPM
- 1D
- 3.34%
- 1M
- 0.48%
- YTD
- -2.59%
- 6M
- -0.70%
- 1Y
- 19.95%
- 3Y*
- 33.76%
- 5Y*
- 16.21%
- 10Y*
- 20.04%
MRNA vs. JPM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
MRNA Moderna, Inc. | 74.94% | -29.08% | -58.19% | -44.63% | -29.28% | 143.11% | 434.10% | 28.09% | -17.90% |
JPM JPMorgan Chase & Co. | -2.59% | 37.27% | 44.29% | 30.63% | -12.64% | 27.75% | -5.53% | 47.26% | -5.49% |
Correlation
The correlation between MRNA and JPM is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.26 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.26 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Dec 10, 2018 | 0.16 |
The correlation between MRNA and JPM shifts across timeframes, from 0.16 (all time) to 0.26 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
MRNA:
$20.38B
JPM:
$868.53B
MRNA:
-$8.16
JPM:
$21.08
MRNA:
9.07
JPM:
3.05
MRNA:
2.75
JPM:
2.52
MRNA:
$2.23B
JPM:
$285.09B
MRNA:
-$309.00M
JPM:
$173.52B
MRNA:
-$3.02B
JPM:
$81.46B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MRNA vs. JPM — Risk / Return Rank
MRNA
JPM
MRNA vs. JPM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and JPMorgan Chase & Co. (JPM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MRNA | JPM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.47 | ||
| Sortino ratioReturn per unit of downside risk | +0.92 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.17 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 2.53 | 1.30 | +1.23 |
| Martin ratioReturn relative to average drawdown | 5.00 | 3.09 | +1.91 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MRNA | JPM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.40 | 0.93 | +0.47 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.37 | 0.67 | -1.03 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.73 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.20 | 0.34 | -0.14 |
Drawdowns
MRNA vs. JPM - Drawdown Comparison
The maximum MRNA drawdown since its inception was -95.38%, which is greater than JPM's maximum drawdown of -76.16%. Use the drawdown chart below to compare losses from any high point for MRNA and JPM.
Loading charts...
Drawdown Indicators
| MRNA | JPM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.38% | -76.16% | -19.22% |
Max Drawdown (1Y)Largest decline over 1 year | -35.51% | -15.47% | -20.04% |
Max Drawdown (3Y)Largest decline over 3 years | -86.58% | -24.42% | -62.16% |
Max Drawdown (5Y)Largest decline over 5 years | -95.38% | -38.77% | -56.61% |
Max Drawdown (10Y)Largest decline over 10 years | — | -43.63% | — |
Current DrawdownCurrent decline from peak | -89.35% | -6.61% | -82.74% |
Average DrawdownAverage peak-to-trough decline | -56.66% | -17.62% | -39.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.90% | 6.47% | +11.43% |
Volatility
MRNA vs. JPM - Volatility Comparison
Moderna, Inc. (MRNA) has a higher volatility of 18.65% compared to JPMorgan Chase & Co. (JPM) at 7.21%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than JPM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MRNA | JPM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.65% | 7.21% | +11.44% |
Volatility (6M)Calculated over the trailing 6-month period | 48.15% | 17.47% | +30.68% |
Volatility (1Y)Calculated over the trailing 1-year period | 64.07% | 21.65% | +42.42% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 66.39% | 24.45% | +41.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.92% | 27.39% | +44.53% |
Dividends
MRNA vs. JPM - Dividend Comparison
MRNA has not paid dividends to shareholders, while JPM's dividend yield for the trailing twelve months is around 1.90%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
JPM JPMorgan Chase & Co. | 1.90% | 1.72% | 1.92% | 2.38% | 2.98% | 2.34% | 2.83% | 2.37% | 2.54% | 1.91% | 2.13% | 2.54% |
MRNA Moderna, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
MRNA vs. JPM - Financials Comparison
This section allows you to compare key financial metrics between Moderna, Inc. and JPMorgan Chase & Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MRNA and JPM have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MRNA has higher volatility (18.65%) compared to JPM (7.21%). In terms of maximum drawdown, MRNA dropped -95.38% vs JPM's -76.16%.
MRNA currently has the higher Sharpe Ratio (1.40 vs 0.93), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MRNA and JPM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer